NLRP3 and cardiac hypertrophy: MCC950 could significantly decrease pressure overload-induced VA vulnerability by reversing HF-induced cardiac hypertrophy, fibrosis, electrical remodeling, and ion channel remodeling via inhibition of the NLRP3 inflammasome.